Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 8/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25734620 | 0.98 | PAOX (0.48) | PAOXADRA1AKDM4EMAPK1HIF1A | |
| SCHEMBL25734619 | 0.91 | ALDH1A1 (0.41) | PAOXKDM4EMAPK1HIF1APOLB | |
| SCHEMBL16491136 | 0.83 | ADRA1A (0.55) | ADRA1AALDH1A1PRMT1 | |
| SCHEMBL13610844 | 0.83 | ADRA1A (0.55) | ADRA1AALDH1A1PRMT1 | |
| SCHEMBL13993954 | 0.81 | ALDH1A1 (0.45) | PAOXKDM4EPOLBALDH1A1ACHE | |
| SCHEMBL13884353 | 0.81 | POLB (0.38) | ADRA1APOLBALDH1A1HRH4HRH3 | |
| SCHEMBL16587322 | 0.81 | POLB (0.38) | ADRA1APOLBALDH1A1HRH4HRH3 | |
| SCHEMBL12664983 | 0.81 | POLB (0.38) | ADRA1APOLBALDH1A1HRH4HRH3 | |
| SCHEMBL24621821 | 0.81 | POLB (0.38) | ADRA1APOLBALDH1A1HRH4HRH3 | |
| SCHEMBL13884340 | 0.81 | POLB (0.38) | ADRA1APOLBALDH1A1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | PAOX 994/4885ADRA1A 4651/4885KDM4E 2547/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | PAOX 1640/4885ADRA1A 193/4885KDM4E 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.